Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07129603

Investigation of the Role of Inflammatory Markers in the Early Detection of Cerebral Vasospasm, Delayed Cerebral Ischemia, and Meningitis Associated With External Cerebrospinal Fluid Drainage After Non-Traumatic Subarachnoid Hemorrhage - A Prospective Case-Control Study

Background Non-traumatic subarachnoid haemorrhage (SAH) is frequently complicated by delayed cerebral ischaemia (DCI) and by ventriculitis/meningitis when external CSF drains are used; bedside TCCD has limited accuracy for vasospasm detection, creating a need for early biomarkers.

Objective To assess the predictive and diagnostic performance of IL-6, IL-1β, TNFα, procalcitonin (PCT), C-reactive protein (CRP) and adrenomedullin (ADM) measured in CSF and serum for vasospasm, DCI, and drain-associated ventriculitis/meningitis after SAH; to test whether combining biomarkers improves accuracy versus routine parameters; and to explore associations with admission and day-14 serum 25-hydroxy-vitamin D.

Methods Prospective case-control study at the University of Debrecen (planned n≈100; enrolment 01-Nov-2024-31-Dec-2029). Adults with angiography-verified SAH requiring lumbar/ventricular drainage are included; traumatic SAH, prior 6-month meningitis, and immunosuppression are excluded. TCCD is performed daily for 14 days; suspected vasospasm is defined by mean flow velocity >120 cm/s, severe by >200 cm/s, with monitoring extended to day 21 if severe. Sampling: daily CSF IL-6/PCT/CRP until drain removal; IL-1β/TNFα/ADM at 0-2, 3-5, 6-8, 9-11, 12-14 days and at meningitis detection; serum 25-OH-D on drain insertion day and day 14. Outcomes at days 30/90/180: mortality, GOSE, Barthel, Karnofsky, mRS. Statistics: normality testing; t-test or non-parametric equivalents; χ² with Yates' correction; Bonferroni for multiplicity; ROC analysis for diagnostic/predictive performance.

Endpoints DCI: new unexplained CT ischaemia or a new unexplained neurological deficit >1 h. Drain-associated infection: infectologist-adjudicated ventriculitis/meningitis. Vasospasm: TCCD-suggested or DSA-confirmed.

Expected impact An accessible CSF/serum biomarker panel may enable earlier risk stratification and treatment for vasospasm, DCI, and drain-associated infections, and inform future randomized trials of vitamin-D supplementation in SAH.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Debrecen, Department of Anesthesiology and Intensive Care

Debrecen, 4032, Hungary

Location status: Recruiting

Location contact

Anna Eszter Abuczki, medical student

SUB_INVESTIGATOR

Béla Fülesdi, MD PhD Full Professor DSc

SUB_INVESTIGATOR

Béla Nagy, MD PhD Associate Professor

SUB_INVESTIGATOR

Csilla Molnár, MD PhD Full Professor

CONTACT

[email protected]

+36302998097

Csilla Molnár, MD PhD Full Professor

PRINCIPAL_INVESTIGATOR

Dorottya MSzántó, MD

CONTACT

[email protected]

+36309990718

Dorottya Szántó, MD

SUB_INVESTIGATOR

Ferenc Bodnár, MD

SUB_INVESTIGATOR

Judit Gál, MD PhD

SUB_INVESTIGATOR

Nikolett Noémi Kóti, MD

SUB_INVESTIGATOR

Nóra Czakó, MD

SUB_INVESTIGATOR

Péter Síró, MD PhD

SUB_INVESTIGATOR

Zsuzsa Bagoly, MD PhD Associate Professor

SUB_INVESTIGATOR

Zsuzsa Jakab, MD

SUB_INVESTIGATOR

About this study

Brief Summary This single-centre prospective case-control study will evaluate whether a CSF/serum biomarker panel (IL-6, IL-1β, TNFα, PCT, CRP, adrenomedullin) can improve the early diagnosis and risk stratification of cerebral vasospasm, delayed cerebral ischaemia (DCI), and drain-associated ventriculitis/meningitis in adults treated for non-traumatic SAH with external CSF drainage. The study also explores associations with serum 25-hydroxy-vitamin D.

Detailed Description Background: Bedside TCCD is non-invasive but has limited accuracy for vasospasm; DSA is the gold standard but invasive and not easily repeatable. Early, reliable biomarkers could identify high-risk patients sooner. External CSF drainage is standard after SAH but carries a 5-22% risk of ventriculitis/meningitis.

Objectives: Assess diagnostic/predictive performance (including ROC analyses) of IL-6, IL-1β, TNFα, PCT, CRP and adrenomedullin (ADM) in CSF and serum for vasospasm, DCI and drain-associated infection; compare against routine parameters; evaluate combined-biomarker utility; explore associations with 25-OH-vitamin D.

Sampling/monitoring: Daily TCCD for 14 days (extend to day 21 if severe vasospasm); suspected vasospasm if MFV >120 cm/s, severe if >200 cm/s. CSF IL-6/PCT/CRP daily until drain removal; IL-1β, TNFα, ADM at 0-2, 3-5, 6-8, 9-11, 12-14 days and at infection detection; serum 25-OH-vitamin D on drain-insertion day and day 14. Outcomes collected at days 30/90/180 (mortality, GOSE, Barthel, Karnofsky, mRS).

Study Type Observational (Prospective; Case-Control).

Observational Model / Time Perspective Case-Control; Prospective.

Estimated Enrollment

~100 participants.

Outcome Measures Primary Outcome Measures Vasospasm occurrence (binary): TCCD suggestive (MFV >120 cm/s; severe >200 cm/s) and/or DSA-confirmed; diagnostic/predictive performance of biomarkers (e.g., ROC AUC). Time Frame: first 14 days post-ictus (to day 21 if severe vasospasm).

Delayed cerebral ischaemia (DCI) (binary): new unexplained ischaemia on native cranial CT or new unexplained neurological deficit lasting >1 hour; biomarker performance vs DCI status. Time Frame: during acute hospital course (typically within first 14 days).

Drain-associated ventriculitis/meningitis (binary): infectologist-adjudicated diagnosis during drainage; biomarker performance vs infection status. Time Frame: through duration of external drainage.

Secondary Outcome Measures Functional outcomes: mortality; Extended Glasgow Outcome Scale; Barthel Index; Karnofsky; modified Rankin Scale at days 30/90/180 post-ictus.

Comparative accuracy: biomarkers vs routine CSF/blood parameters (e.g., CSF cell count/composition/lactate; albumin & glucose ratios; serum CRP/PCT/IL-6).

Combined-biomarker utility: added value of multi-marker panels over single markers.

Vitamin D exploratory analysis: correlation of biomarkers with admission and day-14 serum 25-OH-vitamin D.

Biospecimen CSF and blood samples collected for biomarker measurements (lab values used for analysis).

Eligibility Criteria

Inclusion:

  • Adults (≥18 years).
  • Angiography-identifiable non-traumatic SAH (regardless of source).
  • Requires lumbar or ventricular drain as part of treatment.

Exclusion:

  • Traumatic SAH.
  • Patient/legal representative does not consent.
  • Meningitis within 6 months prior to ictus.
  • Immunosuppressed state (disease or medications affecting WBC number/function).

Groups/Cohorts (for analyses)

  • Vasospasm (+/-) (TCCD-suggested or DSA-confirmed vs. absent).
  • DCI (+/-) (meets DCI definition vs. absent).
  • Drain-associated ventriculitis/meningitis (+/-) (infectologist-adjudicated vs. excluded).

Statistical Plan Normality testing; t-test or non-parametric equivalents; χ² with Yates' correction where appropriate; Bonferroni for multiplicity; ROC analysis for diagnostic/predictive performance.

Location University of Debrecen, Clinical Centre - Department of Anaesthesiology and Intensive Care, Debrecen, Hungary (Neurosurgical Intensive Care Unit).

Contacts Principal Investigator: Prof. Dr. Csilla Molnár - University of Debrecen, Clinical Centre, Department of Anaesthesiology and Intensive Care. (Phone/Email per site policy.)

Keywords Subarachnoid haemorrhage; vasospasm; delayed cerebral ischaemia; ventriculitis; meningitis; IL-6; IL-1β; TNFα; procalcitonin; CRP; adrenomedullin; CSF biomarkers; TCCD; vitamin D.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (≥18 years).
  • Angiography-identifiable non-traumatic SAH (regardless of source).
  • Requires lumbar or ventricular drain as part of treatment.

Exclusion criteria

  • Traumatic SAH.
  • Patient/legal representative does not consent.
  • Meningitis within 6 months prior to ictus.
  • Immunosuppressed state (disease or medications affecting WBC number/function).

Treatment and study plan

Primary outcomes

  1. DCI

    Time frame: 30 days

Study contacts

Contact information is provided by the study sponsor or research team.

Csilla Molnár, MD PhD Full Professor

CONTACT

[email protected]

+36302998097

Dorottya Szántó, MD

CONTACT

[email protected]

+36309990718

Sponsors and collaborators

Lead sponsor

Tamas Vegh, MD

Other

Registry information

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Aug 19, 2025
Registry last updated
Aug 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.